Skip to content

Very Low Nicotine Cigarettes in Smokers With Schizophrenia

Very Low Nicotine Cigarettes in Smokers With Schizophrenia

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02019459
Enrollment
58
Registered
2013-12-24
Start date
2014-11-17
Completion date
2017-08-31
Last updated
2018-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Dependence

Brief summary

Smokers with serious mental illness including those with schizophrenia and bipolar disorder infrequently attempt and attain sustained smoking abstinence and have a 25-year shorter lifespan due to smoking-related illness. This study will examine whether reducing the nicotine content of cigarettes to non-addicting levels is a viable method of reducing smoking in smokers with serious mental illness. Smokers will be randomized to one of two experimental conditions: 1) very low nicotine content (VLNC) cigarettes or 2) normal nicotine content (NNC) cigarettes. Participants will be assessed for patterns of tobacco use, biomarkers of exposure, subjective responses (e.g., satisfaction, craving, withdrawal symptoms), psychiatric symptoms, cognitive performance, smoking cue reactivity and smoking topography.

Interventions

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Pittsburgh
CollaboratorOTHER
Brown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-70 * Schizophrenia, schizoaffective disorder or bipolar disorder * Smoke an average of at least 10 cigarettes per day for at least 1 year * Breath carbon monoxide (CO) levels \>8 ppm (if ≤ 8 ppm, then nicotine (NicAlert) Strip \> 2)

Exclusion criteria

* Pregnant or nursing * Seeking treatment for smoking * Medical contraindications

Design outcomes

Primary

MeasureTime frame
Number of cigarettes smoked per dayEnd of 6 week intervention

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026